What question did this study set out to answer?

The research aims to prepare and evaluate a cost-effective PET imaging agent using 64Cu-labeled bisphosphonate amide for skeletal imaging.

April 13, 2026Scientific ReportsOpen Access

Preparation and evaluation of 64CuCu-labeled bisphosphonate amide of DOTA using reactor-produced 64Cu as an affordable skeletal PET imaging agent

View Full Paper

Ask AI

Bookmark

Authors

Evaluates a new PET imaging agent for detecting skeletal metastases, suggesting a cost-effective alternative.

The research aims to prepare and evaluate a cost-effective PET imaging agent using 64Cu-labeled bisphosphonate amide for skeletal imaging.
Synthesis of 64Cu-labeled BPAMD using low specific activity reactor-produced 64Cu.
Optimization of radiolabeling conditions to achieve high radiochemical purity (> 95%).
Conducting hydroxyapatite binding affinity analysis and in vivo evaluation using healthy Wistar rats.
Achieved high radiochemical purity and excellent in vitro stability of [64Cu]Cu-BPAMD.
Demonstrated higher hydroxyapatite binding affinity compared to the DOTMP complex.
Showed selective bone uptake and rapid clearance from non-target organs in vivo evaluations.

Shetty et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark